DJIA 16,204.97 -211.61 -1.29%
NASDAQ 4,363.14 -146.42 -3.25%
S&P 500 1,880.05 -35.40 -1.85%
market minute promo

Geron Corp (NASDAQ: GERN)

2.86 -0.09 (-3.05%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GERN $2.86 -3.05%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.95
Previous Close $2.95
Daily Range $2.85 - $2.95
52-Week Range $2.60 - $5.30
Market Cap $452.5M
P/E Ratio 0.00
Dividend (Yield) $0.00 (0.0%)
Volume 2,107,075
Average Daily Volume 2,863,142
Current FY EPS -$0.04

Sector

Healthcare

Industry

Drug Makers

Geron Corp (GERN) Description

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. Website: http://www.geron.com/

News & Commentary Rss Feed

Shares of Incyte Corporation Plummeted in January -- Here's Why

A midstage trial for Incyte came to a grinding halt in January, but the company may have a far bigger concern to contend with down the line.

2 Beaten-Down Biotech Stocks to Buy in February

Bellicum Pharmaceuticals and Geron Corp. are intriguing speculative buys after getting trounced in January.

Nick's Picks 2016: Happily Overweight With Healthcare

2 Speculative Small-Cap Biotech Stocks That Could Double

These biotechs have no approved products yet, but they do have collaborations and clinical results that suggest their shares could be big winners down the road.

Geron Up, Myelodysplastic Syndromes Phase II/III Study Begins

Geron Mixed After Company Announces Start Of Phase 2/3 Clinical Trial

Johnson & Johnson's CEO Just Tipped His Cap in a Big Way Regarding M&A

While presenting at the J.P. Morgan Healthcare Conference, CEO Alex Gorsky laid out critical details to J&J's acquisition strategy.

Geron: What To Expect From Imetelstat Now

Monday's ETF with Unusual Volume: DWAS

No JP Morgan Conference Love for Ionis Pharmaceuticals Inc, Geron Corporation, and Medivation Inc

Apparently, no news is bad news.

See More GERN News...

GERN's Top Competitors

GERN $2.86 (-3.05%)
Current stock: GERN
AMGN $145.04 (-3.25%)
Current stock: AMGN
GILD $85.14 (-1.78%)
Current stock: GILD
BIIB $263.86 (-3.44%)
Current stock: BIIB